Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM)
TEVA CANADA LIMITED
A02BC02
PANTOPRAZOLE
40MG
TABLET (DELAYED-RELEASE)
PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) 40MG
ORAL
30/100
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0133229001; AHFS:
APPROVED
2015-11-16
_ _ TEVA-PANTOPRAZOLE MAGNESIUM (pantoprazole magnesium) Page 1 of 55 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-PANTOPRAZOLE MAGNESIUM Pantoprazole Magnesium Enteric-Coated Tablets Tablets, 40 mg pantoprazole (as pantoprazole magnesium), Oral Proton Pump Inhibitor Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Date of Initial Authorization: NOV 16, 2015 Date of Revision: NOV 21, 2023 www.tevacanada.com Submission Control Number: 277792 _ _ TEVA-PANTOPRAZOLE MAGNESIUM (pantoprazole magnesium) _ _ _Page 2 of 55_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Immune 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ......................................................... 5 4.4 Administration .......................................................................... Baca dokumen lengkapnya